The role of 5ht2c receptors in affective disorders

Bibliography

• MOLINEAUX SM, JESSEL TM, AXEL R, JULIUS D: The 5-HTic receptor is a prominent serotonin receptor subtype in the central nervous system. Proc. Natl. Acad. Sci USA (1989) 86:6793–6797.
   PubMed Web of Science ®Google Scholar
• •First report on the predominant brain localization of 5-HT2C receptors.
   Google Scholar
• HOYER D, CLARKE DE, FOZARD JR et al.: International union of pharmacology classification of receptors for 5-hydroxyhyptamine. Pharmacol. Rev. (1994) 46:157–203.
   PubMed Web of Science ®Google Scholar
• BAXTER G, KENNETT GA, BLANEY F, BLACKBURN T: 11T2 receptor subtypes: a family re-united? Trends Phar-macol. Sci. (1995)16:105–110.
   Google Scholar
• POMPEIANO M, PALACIOS JM, MENGOD G: Distribution of the serotonin 5-11T2 receptor family mRNAs: com-parison between 5-HT2A and 5-11T2c receptors. Mol. Brain Res. (1994) 23:163–178.
   PubMedGoogle Scholar
• MENGOD G, NGUYEN H, LE H, WAEBER C, LOBBERT H, PALACIOS JM: The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neu-roscience (1990) 15:577–591.
   Google Scholar
• ABRAMOWSKI D, RIGO M, DUC D, HOYER D, STAUFEN-BIEL M: Localization of the 5-hydroxytryptamine 2c re-ceptor protein in human and rat brain using specific antisera. Neuropharmacology (1995) 34: 1635-1645.
   Google Scholar
• WOLF WA, SCHUTZ LJ: The serotonin 5-11T2c receptor is a prominent serotonin receptor in basal ganglia: evi-dence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J. Neurochem. (1997) 69:1449–1458.
   PubMed Web of Science ®Google Scholar
• SHARMA A, PUNHANI T, FONE KCF: Distribution of the 5-hydroxytryptamine 2c receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7-dihydroxytryptamine. Synapse (1997) 27:45–56.
   PubMed Web of Science ®Google Scholar
• MILATOVICH A, HSIEH CL, BONAMINIO G et al: Sero-tonin receptor 1C gene assigned to X chromosome in human (band q24) and mouse (bands D-F4). Hum. Mol. Genet. (1992) 9:681–684.
   Google Scholar
• LAPPALAINEN J, ZHANG L, DEAN M et al: Identification, expression, and pharmacology of a Cys23-Ser23 sub-stitution in the human 5-11T2c receptor gene (5-HTR2c). Genomics (1995) 27:274–279.
   PubMed Web of Science ®Google Scholar
• •Suggestion of a possible association between genetic varia-tion of the 5-HT2C receptor and disease or response to drug treatment.
   Google Scholar
• JENCK F, MOREAU JL, MUTEL V, MARTIN JR, HAEFELY WE: Evidence for a role of 5-HTic receptors in the antisero-tonergic properties of some antidepressant drugs. Eur. Pharmacol (1993) 231:223–229.
   PubMed Web of Science ®Google Scholar
• AKIYOSHI J, ISOGAWA K, YAMADA K, NAGAYAMA H, FU-JII I: Effects of antidepressants on intracellular Ca++ mobilization in CHO cells transfected with the human 5-11T2c receptors. Biol. Psychiatry (1996) 39:1000–1008.
   PubMed Web of Science ®Google Scholar
• PALVIMAKI EP, ROTH BL, MAJASUO H et al: Interactions of selective serotonin reuptake inhibitors with the se-rotonin 5-11T2c receptor. Psychopharmacology (1996) 126:234–240.
   PubMed Web of Science ®Google Scholar
• CANTON H, VERRIELE L, COLPAERT FC: Binding of typi-cal and atypical antipsychotics to 5-HTic and 5-11T2 sites: clozapine potently interacts with 5-HT1C sites. Eur. J. Pharmacol. (1990) 191:93–96.
   PubMed Web of Science ®Google Scholar
• KUOPPAMAKI M, SYVALAHTI E, HIETALA J: Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur. J. Pharmacol. Mol. Pharmacol Sect. (1993) 245:179–182.
   PubMed Web of Science ®Google Scholar
• MOREAU JL, JENCK F, MARTIN JR, PERRIN S, HAEFELY WE:Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5-HTic re-ceptor activation in rats. Psychopharmacology (1993) 110:140–144.
   PubMed Web of Science ®Google Scholar
• FONE KCF, SHALDERS K, FOX ZD, ARTHUR R, MARSDENCA: Increased 5-11T2c receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology (1996) 123:346–352.
   PubMed Web of Science ®Google Scholar
• BARKER EL, SANDERS-BUSH E: 5-Hydroxytryptamine 1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-) -144 -bromo-2,5-dimethoxypheny0-2--aminopropane. Mol. Pharmacol. (1993) 44:725–730.
   PubMed Web of Science ®Google Scholar
• BARKER EL, WESTPHAL RS, SCHMIDT D, SANDERS-BUSH E: Constitutively active 5-hydroxytryptamine 2c recep-tors reveal novel inverse agonists activity of receptor ligands. J. Biol. Chem. (1994) 269:11687–11690.
   PubMed Web of Science ®Google Scholar
• •Interesting report on the inverse agonistic properties of re-ceptor antagonists such as mianserin.
   Google Scholar
• PRANZATELLI MR, MURTHY JN, TAILOR PT: Novel regula- tion of 5-HTic receptors: down regulation induced both by 5-HT1C/2 receptor agonists and antagonists. Eur. J. Pharmacol. Mol. Pharmacol Sec. (1993) 244:1–5.
   PubMed Web of Science ®Google Scholar
• •First report describing an atypical regulation of the 5-HT2C receptor.
   Google Scholar
• MAREK GJ, MCDOUGLE CJ, PRICE LH, SEIDEN LS: A com-parison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (1992) 109:1–11.
   Google Scholar
• WESTPHAL RS, SANDERS-BUSH E: Reciprocal binding properties of 5-hydroxytryptamine type 2c receptor agonists and inverse agonists. J. Pharmacol. Exp. Ther. (1994) 46:937–942.
   Google Scholar
• HUIDOBRO-TORO JP, HARRIS RA: Brain lipids that in-duce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc. Nati Acad. ScL USA (1996) 93:8078–8082.
   PubMed Web of Science ®Google Scholar
• •Demonstration of a potential novel mechanism for allosteric modulation of 5-HT2C receptor function in the brain.
   Google Scholar
• BOS M, JENCK F, MARTIN JR et al: Novel agonists of 5-11T2c receptors. Synthesis and biological evaluation of substituted 2-findo1-1-y0-1-methylethylamines and (Indeno [1,2-b]pyrrol-1-3/0-1-methylethyl amines. Improved therapeutics for obsessive compulsive dis-orders. J. Med. Chem. (1997) 40:2762–2769.
   Google Scholar
• •First report describing selective 5-HT2C receptor agonists.
   Google Scholar
• BOS M, STADLER H, WICHMANN J et al: Syntheses of 0-Methylasparvenone-derived serotonin receptor an-tagonists. Helvet. Chem. Acta (1998) 81: 525–538.
   Web of Science ®Google Scholar
• FORBES IT, KENNETT GA, GADRE A et al: N-(1-methyl-5-indoly0-1T-(3-pyridyfiurea hydrochloride: the first se-lective 5HT1C receptor antagonist. J. Med. Chem. (1993) 36:1104–1107.
   PubMed Web of Science ®Google Scholar
• CHARNEY DS, WOODS SW, GOODMAN WK, HENINGERGR: Serotonin function in anxiety. II. Effects of the se-rotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology (1987) 92:14–24.
   Google Scholar
• KAHN RS, ASNIS GM, WETZLER S, VAN PRAAG HM: Neu- roendocrine evidence for serotonin receptor hyper-sensitivity in panic disorder. Psychopharmacology (1988) 96:360–364.
   PubMed Web of Science ®Google Scholar
• KLEIN E, ZOHAR J, GERACI MF, MURPHY DL, UHDE TW: Amdogenic effects of m-CPP in patients with panic dis-order: comparison to caffeine's amdogenic effects. Psychiatry (1991) 30:973–984.
   Google Scholar
• HENINGER GR, CHARNEY DS: mCPP, a 5-HT1B agonist, produces prolactin, cortisol and growth hormone re-lease and biphasic behavioral changes in healthy hu-man subjects. Soc. Neurosci. Abstr. (1985) 11:1256.
   Google Scholar
• BENJAMIN J, GREENBERG BD, MURPHY DL: Daily ad-ministration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its be-havioral, hormonal, cardiovascular and temperature effects. Psychopharmacology (1996) 127:140–149.
   PubMed Web of Science ®Google Scholar
• MELLOW AM, LAWLOR BA, SUNDERLAND T, MUELLER EA,MOLCHAN SE, MURPHY DL: Effects of daily oral m-chlorophenylpiperazine in elderly depressed pa-tients: initial experience with a serotonin agonist. Psychiatry (1990) 28:588–594.
   Web of Science ®Google Scholar
• PIGOTT TA, L'HEUREUX F, BERNSTEIN SE, HILL JL, MUR-PHY DL: A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazine (mCP1) in patients with obsessive-compulsive disor-der. NCDEU Annual Meeting Abstract, (1992) May:26–29.
   Google Scholar
• NUTT D, LAWSON C: Panic attacks. A neurochemicaloverview of models and mechanisms. Br. J. Psychiatry (1992) 160:165–178.
   Google Scholar
• FIORELLA D, HELSLEY S, RABIN RA, WINTER JC: 5-11T2creceptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine. Psycho-pharmacology (1995a) 122:237–243.
   PubMedGoogle Scholar
• GLEASON SD, SHANNON HE. Meta-chlorophenylpiperazine induced changes in locomo-tor activity are mediated by 5-HT1 as well as 5-11T2c re-ceptors in mice. Eur. j Pharmacol (1998) 341:135–138.
   PubMed Web of Science ®Google Scholar
• THOMAS DR, GAGER TL, HOLLAND V, BROWN AM, WOOD MD: m-chlorophenyl-piperazine (mCP1) is an antagonist at the cloned human 5-HT2B receptor. Neu-roreport. (1996) 7:1457–1460.
   PubMed Web of Science ®Google Scholar
• HAMIK A, PEROUTKA SJ: 1-(m-Chlorophenyfi-piper-azine (mCP1) interactions with neurotransmitter re-ceptors in the human brain. Biol. Psychiatry (1989) 25:569–575.
   PubMed Web of Science ®Google Scholar
• WESTENBERG HGM, DEN BOER JA: New findings in thetreatment of panic disorder. Pharmacopsychiatry (1993) 26:30–33.
   Google Scholar
• VAN VLIET IM, WESTENBERG HGM, DEN BOER JA: Effectsof the 5-HT1A receptor agonist flesinoxan in panic dis-order. Psychopharmacology (1996) 127:174–180.
   PubMed Web of Science ®Google Scholar
• •Important report on the effects in man of a full and selective 5-HT1A receptor agonist
   Google Scholar
• DOLBERG OT, SASSON Y, COHEN R, ZOHAR J: The rele-vance of behavioral probes in obsessive-compulsive disorder. Eur.J. Neuropsychopharmacol. (1995) 5(3):161–162.
   Google Scholar
• LOI V, LAI M, PISANO MR, DEL ZOMPO M: Panicogeniceffect of sumatriptan: a pilot study. Pharmacol Res. (1995) 31 (Suppl.):348.
   Google Scholar
• MARCOLI M, MAURA G, TORTAROLO M, RAITERI M: Tra-zodone is a potent agonist at 5-HT2c receptors mediat-ing inhibition of the N-methyl-D-aspartate/nitric oxide/ cyclic GMP pathway in rat cerebellum. J. Phar-macol. Exp. Ther. (1998) in press.
   Google Scholar
• MILLAN MJ, PEGLION JL, LAVIELLE G, PERRIN S: 5-HT2c receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur. J: Pharmacol. (1997) 325:9–12.
   Google Scholar
• MARTIN JR, BOS M, JENCK F et al.: 5-HT2c receptor ago-nists: pharmacological properties and therapeutic po-tential. J. Pharmacol Exp. Ther. (1998) 286:913–924.
   PubMed Web of Science ®Google Scholar
• MOREAU JL, BOS M, JENCK F, MARTIN JR, MORTAS P, WICHMANN J: 5-HT2c receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur. Neuropsychopharma-col. (1996) 6:169–175.
   PubMed Web of Science ®Google Scholar
• JENCK F, MOREAU JL, BERENDSEN HHG et al.: Antiaver-sive effects of 5-HT2c receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur. Neuropsy-chopharmacol (1998) 8:161–168.
   PubMed Web of Science ®Google Scholar
• GOODWIN GM: How do antidepressants affect sero-tonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. j Clin. Psychiatry (1996) 57 (Suppl. 4):9–13.
   Google Scholar
• •SSRIs non-selectively activate numerous 5-HT receptor subtypes
   Google Scholar
• STANFORD SC: Prozac: panacea or puzzle? Trends Phar-macol. ScL (1996) 71:150–154.
   Google Scholar
• PRISCO S, ESPOSITO E: Differential effects of acute andchronic fluoxetine administration on the spontane-ous activity of dopaminergic neurons in the ventral tegmental area. Br. J. Pharmacol (1995) 116:1923–1931.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G, MOREAU JL, JENCK F, MISSLIN R, MARTIN JR:Acute and chronic treatment with 5-HT reuptake in-hibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology (1994) 113:463–470.
   PubMed Web of Science ®Google Scholar
• ALLIKMETS L, MATTO V, HARRO J: Do the antidepres-sants have anxiogenic action? Biol. Psychiatry (1996) 39:626.
   Google Scholar
• BROMIDGE SM, DABBS S, DAVIES DT et al.: Novel and se-lective 5-HT2c/2B receptor antagonists as potential amdolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of sub-stituted 1-(3-pyridylcarbamoy0 indolines. J. Med. Chem. (1998) 41:1598–1612.
   PubMed Web of Science ®Google Scholar
• KENNETT GA, WOOD MD, GLEN A et al.: In vivo proper-ties of SB 200646A, a 5-HT2c/2B receptor antagonist. Br. Pharmacol. (1994) 111:797–802.
   PubMed Web of Science ®Google Scholar
• KENNETT GA, BAILEY F, PIPER DC, BLACKBURN TP: Ef-fect of SB 200646A, a 5-11T2c/5-HT2a receptor antago-nist in two conflict models of anxiety. Psychopharmacology (1995) 118:178–182.
   PubMedGoogle Scholar
• KENNETT GA, WOOD MD, BRIGHT F et al: SB 24084, a se-lective and brain penetrant 5-11T2c receptor antago-nist. Neuropharmacology (1997) 36:609–620.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G, PERRAULT G, SANGER DJ: A comparative study of the effects of selective and non-selective 5-11T2c receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacol. (1997) 36:793–802.
   PubMed Web of Science ®Google Scholar
• BOS M, CANESSO R, INOUE-OHGA N et al.: 0 - Methylasparvenone, a nitrogen-free serotonin antago-nist. Bioorgan. Med. Chem. (1997) 5:2165–2171.
   PubMed Web of Science ®Google Scholar
• HUIDOBRO-TORO JP, VALENZUELA CF, HARRIS RA: Modulation of GABAA receptor function by G-protein coupled 5-11T2c receptors. Neuropharmacology (1996) 35:1355–1363.
   PubMed Web of Science ®Google Scholar
• PALVIMAKI EP, MAJASUO H, KUOPPAMAKI M, MAN-NISTO PT, SYVALAHTI E, HIETALA J: Deramciclane, a pu-tative amdolytic drug, is a serotonin 5-11T2c receptor inverse agonist but fails to induce 5-11T2c receptor down-regulation. Psychopharmacology (1998) 136:99–104.
   PubMedGoogle Scholar
• •First description of a 5-HT2C receptor inverse agonist with in vivo anxiolytic-like properties.
   Google Scholar
• STAHL SM: Serotonin: it's possible to have too much of a good thing. J. Clin. Psychiatry (1997) 58:520–521
   PubMed Web of Science ®Google Scholar
• •A concise and simple graphical view of the role of 5-HT in affective disorders.
   Google Scholar
• FIORELLA D, RABIN RA, WINTER JC: The role of the 5-HT2A and 5-11T2c receptors in the stimulus effects of hallucinogenic drugs. I: antagonist correlation analy-sis. Psychopharmacology (1995b) 121:347–356.
   Google Scholar
• NEWTON RA, PHIPPSSL, FLANIGAN TP et al.: Characteri-zation of human 5-hydroxytryptamine 2A and 5-hydroxytryptamine 2c receptors expressed in the hu-man neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. J. Neurochem. (1996) 67:2521–2531.
   PubMed Web of Science ®Google Scholar
• WAINSCOTT DB, COHEN ML, SCHENCK KW et al.: Phar-macological characteristics of the newly cloned rat 5-hydroxytryptamine 2F receptor. Mol. Pharmacol. (1993) 43:419–426.
   PubMed Web of Science ®Google Scholar
• ELLIS ES, BYRNE C, MURPHY OE, TILFORD NS, BAXTERGS: Mediation by 5-hydroxyhyptamine 2B receptors of endothelium-dependent relaxation in rat jugular vein. Br. J. Pharmacol (1995) 114:400–404.
   PubMed Web of Science ®Google Scholar
• KENNETT GA, BRIGHT F, TRAIL B, BAXTER GS, BLACK-BURN TP: Effects of the 5-HT2B receptor agonist BW 723C86 on three rat models of anxiety. Br. J. Pharmacol. (1996) 117:1443–1448.
   PubMed Web of Science ®Google Scholar
• DEAKIN JWF, GRAEFF FG: 5-HT and mechanisms of de-fence. J. Psychopharmacology (1991) 5:305–315.
   PubMedGoogle Scholar
• •Important review suggesting that 5-HT has a complex, dual action on the neural mechanisms of anxiety by either facili-tating or inhibiting different kinds of anxiety in different brain regions.
   Google Scholar
• BECKETT SRG, LAWRENCE AJ, MARSDEN CA, MARSHALL PW: Attenuation of chemically induced defence re-sponse by 5-HT1 receptor agonists administered into the periaqueductal gray. Psychopharmacology (1992) 108:110–114.
   PubMed Web of Science ®Google Scholar
• GRAEFF FG, GUIMARAES FS, DE ANDRADE TGCS, DEAKIN JWF: Role of 5-HT in stress, anxiety and de-pression. Pharmacol. Biochem. Behav. (1996) 54:129–141.
   PubMed Web of Science ®Google Scholar
• GUIMARAES FS, MBAYA PS, DEAKIN JFW: Ritanserin fa-cilitates anxiety in a simulated public-speaking para-digm. J. Psychopharmacol. (1997) 11:225–231.
   PubMed Web of Science ®Google Scholar
• MORA PO, FERREIRA NETTO C, GRAEFF FG: Role of 5-HT2A and 5-11T2c receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem. Behav. (1997) 58:1051–1057.
   PubMed Web of Science ®Google Scholar
• TECOTT LH, SUN LM, AKANA SF et al.: Eating disorder and epilepsy in mice lacking 5-11T2c serotonin recep-tors. Nature (1995) 374:542–546.
   PubMed Web of Science ®Google Scholar
• KUOPPAMAKI M, PALVIMAKI EP, SYVALAHTI E, HIETALA J: 5-HT1C receptor-mediated phosphoinositide hy-drolysis in the rat choroid plexus after chronic treat-ment with clozapine. Eur. J. Pharmacol. (1994) 255:91–97.
   PubMed Web of Science ®Google Scholar
• SCHUTZ W, FREISSMUTH M: Reverse intrinsic activity of antagonists on G-protein-coupled receptors. Trends Pharmacol. Sci. (1992) 13:376–380.
   PubMed Web of Science ®Google Scholar
• LEFKOWITZ RJ, COTECCHIA S, SAMANA P, COSTA T: Con-stitutive activity of receptors coupled to guanine nu-cleotide regulatory proteins. Trends Pharmacol. ScL (1993) 14:303–307.
   PubMed Web of Science ®Google Scholar
• MILLIGAN G, BOND RA, LEE M: Inverse agonism: phar-macological curiosity or potential therapeutic strat-egy? Trends Pharmacol Sci. (1995) 16:10–13.
   Google Scholar
• •Important review on the therapeutic potential of inverse agonists.
   Google Scholar
• MILLIGAN G, BOND RA: Inverse agonism and the regu- lation of receptor number. Trends Pharmacol. Sci. (1997) 18:468–474.
   PubMed Web of Science ®Google Scholar
• HERRICK-DAVIS K, EGAN C, TEITLER M: Activating mu- tations of the serotonergic 5-11T2c receptor. J. Neuro-chem. (1997) 69:1138–1144.
   PubMed Web of Science ®Google Scholar
• •Recent point mutation experiment showing that 5-HT2C re-ceptors can be rendered constitutively active aminoacid substitution in the intracellular loops involved in G-protein coupling. Mutations in the 5-HT2C receptor may generate pathophysiological states.
   Google Scholar
• WELSH SE, ROMANO AG, HARVEY JA: Effects of sero-tonin 5-HT2A/2c antagonists on associative learning in the rabbit. Psychopharmacology (1998) 137:157–163.
   PubMed Web of Science ®Google Scholar
• WILSON SJ, LILLYVVHITE AR, POTOKAR JP, NUTT DJ: Adult night terrors and paroxetine. Lancet (1997) 350 (9072):185.
   PubMed Web of Science ®Google Scholar
• BUYDENS-BRANCHEY L, BRANCHEY M, FERGESON P, HUDSON J, MCKERNIN C: the meta-chlorophenylpiperazine challenge test in cocaine ad-dicts : hormonal and psychological responses. Biol. Psychiatry (1997) 41:1071–1086.
   PubMed Web of Science ®Google Scholar
• COWEN PJ, CLIFFORD EM, WILIAMS C, WALSH AES, FAIR-BURN CG: Why is dieting so difficult? Nature (1995) 376:567.
   Google Scholar
• BURNET PWJ, HARRISON PJ, GOODWIN GM et al.: Allelicvariation in the serotonin 5-11T2c receptor gene and migraine. Neuroreport (1997) 8:2651–2653.
   PubMed Web of Science ®Google Scholar
• SODHI MS, ARRANZ MJ, CURTIS D et al.: Association be-tween clozapine response and allelic variation in the 5-11T2c receptor gene. Neuroreport (1995) 7:169–172.
   PubMed Web of Science ®Google Scholar
• MALHOTRA AK, GOLDMAN D, OZAKI N et al.: Clozapine response and the 5-11T2c Cys23Ser polymorphism. Neuroreport (1996) 7:2100–2102.
   PubMed Web of Science ®Google Scholar
• RIETSCHEL M, NABER D, FIMMERS R et al: Efficacy and side-effects of clozapine not associate with variation in the 5-11T2c receptor. Neuroreport (1997) 8: 1999-2003.
   Google Scholar
• BOS M, JENCK F, MARTIN JR et al.: Synthesis, pharmacol-ogy and therapeutic potential of 10-methoxypyrazino[1,2-a]indoles, partial agonists at the 5-HT2C receptor. Eur. J. Med. Chem. (1997) 32:253–261.
   Web of Science ®Google Scholar
• BURNS CM, CHU H, RUETER SM et al.: Regulation of sero-tonin-2c receptor G-protein coupling by RNA editing. Nature (1997) 387:303–308.
   PubMed Web of Science ®Google Scholar
• ••First report on mRNA editing leading to distinct isoforms of5-HT2C receptors. This opens interesting possibilities for distinct biological functions of the differentially edited 5-HT2C receptor isoforms.
   Google Scholar
• MARTIN GR, EGLEN RM, HAMBLIN MW, HOYER D, YOCCA F: The structure and signalling properties of 5-HT receptors: an endless diversity? Trends Pharmacol. Sci. (1998) 19:2–4.
   Google Scholar
• DARMANI NA, MARTIN BR, PANDEY U, GLENNON RA: Dofunctional relationships exist between 5-HT1A and 5-11T2 receptors? Pharmacol. Biochem. Behav. 36: 901-906 (1990).
   Google Scholar
• BERENDSEN HHG, BROEKKAMP CLE: Behavioral evi-dence for functional interactions between 5-HT recep-tor subtypes in rats and mice. Br. J. Pharmacol. (1990) 101:667–673.
   PubMed Web of Science ®Google Scholar
• POMERANTZ SM, HEPNER BC, WERTZ JM: 5-HT1A and5-HT1c/1D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys. Eur. J. Pharmacol. (1993) 243:227–234.
   PubMed Web of Science ®Google Scholar
• MASWOOD S, ANDRADE M, CALDAROLA-PASTUSZKA M,UPHOUSE L: Protective action of the 5-HT 2A/2C receptor agonist DOI on 5-HT1A receptor-mediated inhibition of lordosis behavior. Neuropharmacol. (1996) 35:497–501.
   PubMed Web of Science ®Google Scholar
• BERENDSEN HHG: Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmac. Ther. (1995) 66:17–37.
   Google Scholar
• ARANEDA R, ANDRADE R: 5-hydroxytryptamine2 and 5-hydroxytryptamineu receptors mediate opposing responses on membrane excitability in rat association cortex. Neurosci. (1991) 40:399–412.
   PubMed Web of Science ®Google Scholar
• SELBIE LA, HILL SJ: G-protein coupled receptor cross-talk: the fine-tuning of multiple receptor-signaling pathways. Trends Pharmacol Sci. (1998) 19:87–93.
   PubMed Web of Science ®Google Scholar
• •An important review paper suggesting that functional inter-actions and cross-talk between receptors play a major role in multiple receptor signaling pathways and in vivo effects.
   Google Scholar
• MILLAN MJ, CANTON H, LAVIELLE G: Targeting multiple serotonin receptors: mixed 5-HT1A agonists/ 5-HT1c/2 antagonists as therapeutic agents. DN&P (1992) 5:397–406.
   Google Scholar